Which medications can cause elevated hemoglobin and hematocrit?

Medications That Cause Elevated Hemoglobin and Hematocrit

Erythropoiesis-stimulating agents (ESAs) such as epoetin alfa and darbepoetin alfa are the primary medications that cause elevated hemoglobin and hematocrit, with testosterone replacement therapy being the second most common culprit. 1, 2

Primary Offenders

Erythropoiesis-Stimulating Agents (ESAs)

ESAs directly stimulate red blood cell production and predictably increase hemoglobin and hematocrit levels:

• Epoetin alfa and darbepoetin alfa are FDA-approved for chemotherapy-induced anemia 1, 3
• These agents cause dose-dependent increases in hemoglobin, typically raising levels by 1-2 g/dL over 4-8 weeks 4, 3
• Hemodilution from ESAs causes hemoglobin decreases of 0.8-1.1 g/dL and hematocrit decreases of 2.3-3.6% initially, but the net effect is increased red cell mass 1
• Critical safety concern: ESAs increase thromboembolic event risk significantly—pooled rates show 7% in epoetin-treated patients vs 4% in controls 3

Dosing that increases H&H:

• Epoetin alfa: 150 U/kg SC three times weekly or 40,000 U weekly 3
• Darbepoetin alfa: 2.25 mcg/kg weekly or 500 mcg every 3 weeks 3
• Dose escalation to 300 U/kg TIW (epoetin) or 60,000 U weekly (darbepoetin) further increases hemoglobin 3

Testosterone Replacement Therapy

Testosterone acts as a direct stimulus for erythropoiesis and causes clinically significant increases in hemoglobin and hematocrit 2, 5:

• Hemoglobin increases by 15-20% during male puberty as testosterone levels rise 2
• The effect is dose-dependent and greater in older men than younger hypogonadal men 5
• Route matters significantly: Intramuscular injections cause erythrocytosis in 43.8% of patients vs 15.4% with transdermal patches 2
• Higher doses increase risk: 2.8% erythrocytosis with 5 mg/day transdermal vs 17.9% with 10 mg/day 2

Monitoring requirements: Check hematocrit at baseline, 3-6 months, then annually. Stop therapy if hematocrit exceeds 54% 5

Secondary Medications

SGLT2 Inhibitors

Sodium-glucose cotransporter-2 inhibitors cause modest but consistent increases in hemoglobin and hematocrit 6:

• Mean increase: Hemoglobin +0.68 g/dL and hematocrit +2.15% compared to controls 6
• Mechanism involves hemoconcentration from diuretic effects and volume depletion 7
• Effects are consistent across all SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) 6

Thiazolidinediones (TZDs)

Rosiglitazone and pioglitazone cause decreases in hemoglobin and hematocrit through hemodilution, not increases 8:

• Hemoglobin falls by 0.8-1.1 g/dL with hematocrit decreasing 2.3-3.6% 8
• This occurs due to plasma volume expansion, not effects on erythropoiesis 8
• These drugs do NOT cause elevated H&H—they lower it

Clinical Pitfalls to Avoid

1. Don't confuse hemodilution with true anemia: TZDs and some ESA effects initially cause dilutional decreases before red cell mass increases 8

2. Route of administration matters critically for testosterone: Intramuscular preparations carry nearly 3-fold higher risk of erythrocytosis than transdermal formulations 2, 9

3. ESA-induced polycythemia increases thrombotic risk: For every 15 patients treated with ESAs at 10% baseline thrombotic risk, one additional thromboembolic event occurs 3

4. Altitude affects baseline values: Populations living above 2000 meters have naturally higher hemoglobin/hematocrit that may be misclassified as polycythemia 10

5. Multiple myeloma patients on thalidomide/lenalidomide plus ESAs face particularly high thrombotic risk and require extra caution 3

Monitoring Algorithm

For ESA therapy:

• Measure hemoglobin at baseline and every 2-4 weeks during dose titration 3
• Reduce dose by 25-40% when hemoglobin reaches transfusion-avoidance level or increases >1 g/dL in 2 weeks 3
• Discontinue if no response after 6-8 weeks 4, 3

For testosterone therapy:

• Check hematocrit at baseline, 3-6 months, then annually 5
• Stop therapy if hematocrit >54% until it decreases to safe levels 5
• Evaluate for hypoxia and sleep apnea before restarting at reduced dose 5